ClinicalTrials.gg
Not yet recruitingNCT07857122FEAST-AFTUpdated Oct 5, 2026

Evaluating the Therapeutic Potential of Focal Electrically Administered Seizure Therapy (FEAST) in the Treatment of Depression: A Multicenter Randomized Clinical Trial

An interventional study of Stimulation by the Sigma ECT/FEAST device and Stimulation by Sigmastim ECT 200J device administered in right unilateral (RUL) in Major Depressive Episode (MDE), Unipolar Disorder and Bipolar 1 Disorder, sponsored by Centre Hospitalier St Anne. Not yet recruiting at 5 sites in 2 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Centre Hospitalier St Anne · Not applicable, Interventional, and Treatment

How we know

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

A significant proportion of patients remain resistant to antidepressant therapies, even when treatment is well managed. Electroconvulsive therapy (ECT) is a well-established method for treating certain severe and resistant psychiatric pathologies. ECT is also the gold standard for treating mood disorders. Although effective, it is associated with cognitive side effects (memory impairment, post-ECT confusion, longer reorientation time), particularly with bitemporal (BT) montage and brief pulse stimulation. These effects may contribute to patient reluctance and limit adherence to this therapy. From a mechanistic point of view, ECT causes changes in cerebral blood flow (rCBF) and brain electrical activity, particularly in the prefrontal cortex, where the induction of "pseudo-epileptic seizures" appears to be related to therapeutic efficacy, while cognitive side effects appear to be associated with alterations in the temporal areas. The conventional stimulation method results in widespread diffusion of the current due to the properties of the skull, limiting control over the distribution of intracerebral charge densities. In this context, a new approach called "Focal Electrically Administered Seizure Therapy" (FEAST) has been developed to focus the electrical current and limit cognitive side effects. Unlike traditional ECT, FEAST uses unidirectional current and optimized electrode placement, aiming to induce seizures in a more localized manner in the right prefrontal cortex while reducing propagation to temporal regions.

The FEAST configuration is based on scientific literature (protocols, parameters, electrode positioning) and not on a "pre configured" mode validated by the medical device manufacturer.

Neuroimaging studies suggest that FEAST causes an increase in blood flow in the right prefrontal cortex at the onset of the seizure, followed by a postictal redistribution similar to that observed with ECT, confirming its targeted effect. Open-label clinical trials conducted to date show that FEAST significantly improves depressive symptoms with a more favorable cognitive profile compared to traditional ECT, notably by reducing the impact on autobiographical memory and decreasing the time needed to regain orientation acutely after treatment. Several comparative studies between FEAST and unilateral ultra-brief pulse ECT suggest an advantage in terms of cognitive tolerance, although the differences are not always statistically significant. A multicenter trial also showed comparable effects on reducing suicidal ideation, suggesting that FEAST could be an alternative to traditional ECT. Indeed, preliminary studies indicate that FEAST may offer similar benefits to ECT in terms of reducing depressive symptoms, but with fewer cognitive side effects, which could lead to a better quality of life.

Although these studies are promising, they remain few in number and have methodological limitations (open-label clinical trials, feasibility studies, lack of randomization with a comparator arm, small sample size, or assignment to the study arm based on patient preference). There are currently no other randomized clinical trials on FEAST underway or in preparation worldwide. Well-designed, multicenter clinical trials with sufficient patient numbers to achieve satisfactory statistical power are therefore needed to address the limitations of previous studies and explore the clinical benefits of FEAST.

The present study is therefore a randomized, multicenter, double-blind clinical trial designed to evaluate the superiority of FEAST in terms of safety and efficacy compared to traditional ECT modalities.

Read the detailed description

Depression is a severe and debilitating illness affecting millions of people worldwide. Severe characterized depressive episodes (CDE), particularly those with melancholic or psychotic features, represent a major therapeutic challenge in psychiatry (Belmaker \& Agam, 2008). Although traditional treatments such as antidepressants, mood stabilizers and psychotherapies are effective for some patients, the response to these therapies is often inadequate (Rush et al., 2006). A significant proportion of patients remain resistant to these therapies, even when treatment is well managed. Electroconvulsive therapy (ECT) is a well-established method for treating certain severe and resistant psychiatric pathologies. ECT is also the gold standard for treating mood disorders. Although effective, it is associated with cognitive side effects (memory impairment, post-ECT confusion, longer reorientation time), particularly with bitemporal (BT) montage and brief pulse stimulation (Semkovska et al., 2016) (Sackeim et al., 2008; Nahas et al., 2013; Youssef et al., 2021). These effects may contribute to patient reluctance and limit adherence to this therapy (Nahas et al., 2013; Youssef et al., 2021). From a mechanistic point of view, ECT causes changes in cerebral blood flow (rCBF) and brain electrical activity, particularly in the prefrontal cortex, where the induction of "pseudo-epileptic seizures" appears to be related to therapeutic efficacy, while cognitive side effects appear to be associated with alterations in the temporal areas. The conventional stimulation method results in widespread diffusion of the current due to the properties of the skull, limiting control over the distribution of intracerebral charge densities. In this context, a new approach called "Focal Electrically Administered Seizure Therapy" (FEAST) has been developed to focus the electrical current and limit cognitive side effects (Berman et al., 2005; Spellman et al., 2009; Peterchev et al., 2015). Unlike traditional ECT, FEAST uses unidirectional current and optimized electrode placement, aiming to induce seizures in a more localized manner in the right prefrontal cortex while reducing propagation to temporal regions.

The FEAST configuration is based on scientific literature (protocols, parameters, electrode positioning) and not on a "pre configured" mode validated by the medical device manufacturer.

Neuroimaging studies suggest that FEAST causes an increase in blood flow in the right prefrontal cortex at the onset of the seizure, followed by a postictal redistribution similar to that observed with ECT, confirming its targeted effect. Open-label clinical trials conducted to date show that FEAST significantly improves depressive symptoms with a more favorable cognitive profile compared to traditional ECT, notably by reducing the impact on autobiographical memory and decreasing the time needed to regain orientation acutely after treatment. Several comparative studies between FEAST and unilateral ultra-brief pulse ECT suggest an advantage in terms of cognitive tolerance, although the differences are not always statistically significant. A multicenter trial also showed comparable effects on reducing suicidal ideation, suggesting that FEAST could be an alternative to traditional ECT. Indeed, preliminary studies indicate that FEAST may offer similar benefits to ECT in terms of reducing depressive symptoms, but with fewer cognitive side effects, which could lead to a better quality of life.

Although these studies are promising, they remain few in number and have methodological limitations (open-label clinical trials, feasibility studies, lack of randomization with a comparator arm, small sample size, or assignment to the study arm based on patient preference). There are currently no other randomized clinical trials on FEAST underway or in preparation worldwide. Well-designed, multicenter clinical trials with sufficient patient numbers to achieve satisfactory statistical power are therefore needed to address the limitations of previous studies and explore the clinical benefits of FEAST.

The present study is therefore a randomized, multicenter, double-blind clinical trial designed to evaluate the superiority of FEAST in terms of safety and efficacy compared to traditional ECT modalities.

02

Conditions studied

  • Major Depressive Episode (MDE)
  • Unipolar Disorder
  • Bipolar 1 Disorder

Keywords

  • ECT
  • FEAST
  • randomized
  • quality of life
03

In context

Lead sponsor

Centre Hospitalier St Anne is the lead sponsor of 101 studies on the registry; 55 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 90 years;
  • Moderate-severe MDE as part of a unipolar or bipolar disorder (including psychotic and catatonic features) according to criteria (APA, 2022);
  • Score ≥ 17 at the HDRS-17 at the inclusion interview (HAMILTON, 1960);
  • Ability to understand the clinical investigation plan and comply with study visits;
  • ECT indicated by the referring physician for MDE;
  • Ability to tolerate the necessary adaptations to certain treatments (discontinuation, dosage, frequency of intake) for the proper conduct of ECT/FEAST (lithium, anticonvulsants with the exception of lamotrigine) and the restriction of benzodiazepine dosage to ≤ 3 mg/day of lorazepam equivalent (Boylan et al., 2000, Nahas et al., 2013, Sahlem et al., 2020, Youssef et al., 2021);
  • Written .

Exclusion criteria

Exclusion Criteria:

  • Previous diagnosis of neurologic disease: neurodegenerative disease, epilepsy, encephalopathy, delirium tremens or memory disorder, …;
  • Score \< 23 on the at inclusion interview (Nasreddine et al., 2005);
  • Other neurological diseases affecting the central nervous system or head trauma in progress or having had a cognitive impact according to the anamnesis and the clinician's assessment. This include: space-occupying cerebral lesions, such as tumors or hematomas, cerebrovascular aneurysms or malformations, recent stroke (hemorrhagic or ischemic), other causes of increased intracranial pressure (e.g., hydrocephalus, meningitis, encephalitis), skull defects (which may include metal devices in or near the site of stimulation), metal devices, such as screws and plates or metal meshes, may preclude specific stimulation patterns but may not preclude treatment administration completely, implanted active stimulatory devices (e.g., Deep Brain Stimulation devices). Stimulation devices may pose a risk to the patient if the flow of current during treatment damages active components of the device (i.e. potential for catastrophic failure of the battery);
  • General condition and/or comorbidities not allowing general anesthesia to be performed;
  • Severe and unstable pulmonary conditions increasing the risks of problematic airway management and aspiration during and immediately after ECT according to the anesthesiologist's assessment such as (COPD), asthma, pneumonia;
  • Severe and unstable cardiovascular conditions substantially increasing risks according to the anesthesiologist's assessment, such as recent and/or severe myocardial infarction, unstable angina, uncompensated congestive heart failure, vascular aneurysm or stenosis, arrhythmias, uncontrolled hypertension or hypotension;
  • Concomitant psychotic disorder (schizophrenia, schizoaffective disorder) according to or than MED with psychotic features (APA, 2022);
  • Moderate to severe substance use disorder in the 3 months preceding the inclusion in the study (except caffeine and nicotine) (G. L. Sahlem et al., 2016, Youssef et al., 2021);
  • Rapid-cycling bipolar disorder (Youssef et al., 2021);
  • Having received an acute course of ECT in the 3 months preceding the inclusion in the study;
  • Participation in another interventional research protocol other than magnetic resonance imaging (MRI) studies);
  • Patient deprived of their liberty by judicial or administrative decision;
  • Patient under legal protection;
  • Pregnant and breastfeeding women;
  • Patient not affiliated to a social security or other social protection scheme.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    FEAST

    FEAST stimulation administered with 2 electrodes with Ultrabrief Parameter Set (initial values of 0.30 ms)

    Device: Stimulation by the Sigma ECT/FEAST device

  • Active comparator
    RUL ECT

    ECT stimulation administered in right unilateral with Ultra Brief pulse (0.3 ms)

    Device: Stimulation by Sigmastim ECT 200J device administered in right unilateral (RUL)

  • Active comparator
    BT ECT

    ECT stimulation administered in bilateral with brief pulse (1 ms)

    Device: Stimulation by Sigmastim ECT 200J device administered in bilateral (BT)

Interventions

  • DeviceStimulation by the Sigma ECT/FEAST device

    Titration followed by a charge applied corresponding to 6 times the seizure threshold (6xST) during the second session (first suprathreshold session). Acute treatment (week 1 à 6): FEAST/ECT sessions will take place 3 times a week. Regardless of the intervention group, the research team will recommend that treatment sessions continue until clinical remission is documented, if possible, with a maximum of 18 sessions. The consolidation phase will be carried out according to the effective parameters applied during the cure and the following tapering schedule: one session per week for one month, then one session every two weeks for two months, then one session per month for three months.

  • DeviceStimulation by Sigmastim ECT 200J device administered in right unilateral (RUL)

    Titration followed by a charge applied corresponding to 6 times the seizure threshold (6xST) during the second session (first suprathreshold session). Acute treatment (week 1 à 6): FEAST/ECT sessions will take place 3 times a week. Regardless of the intervention group, the research team will recommend that treatment sessions continue until clinical remission is documented, if possible, with a maximum of 18 sessions. The consolidation phase will be carried out according to the effective parameters applied during the cure and the following tapering schedule: one session per week for one month, then one session every two weeks for two months, then one session per month for three months.

  • DeviceStimulation by Sigmastim ECT 200J device administered in bilateral (BT)

    Titration followed by a charge applied corresponding to 6 times the seizure threshold (1.5xST) during the second session (first suprathreshold session). Acute treatment (week 1 à 6): FEAST/ECT sessions will take place 3 times a week. Regardless of the intervention group, the research team will recommend that treatment sessions continue until clinical remission is documented, if possible, with a maximum of 18 sessions. The consolidation phase will be carried out according to the effective parameters applied during the cure and the following tapering schedule: one session per week for one month, then one session every two weeks for two months, then one session per month for three months.

06

What researchers measure

Primary outcomes

  1. Change from baseline in the Q-LES-Q-SF score at Day 5

    Change in Q-LES-Q-SF score from inclusion to Day 5 (5 days after the last session of the acute phase treatment (Post treatment visit (D5 ± 2 days)). The total raw score ranges from 14 to 70. . The higher the score, the better the person's quality of life and self-reported satisfaction.

    Time frame: From enrollment to the 5 days after the last session of the acute phase treatment (Day 5)

Secondary outcomes

  1. Changes in Hamilton Rating Scale for Depression-17 items (HDRS-17) scores from inclusion to end of study (EOS)

    HDRS-17 (HAMILTON, 1960, Bagby et al., 2004) completed at inclusion (V1), once a week during the acute randomized treatment period (W1 to W6), at the end of the acute randomized treatment period (D5), at M1 and M6 follow-up assessments. The total maximum score is 52, the minimum is 0. . The general clinical thresholds are: ≤7 after treatment = remission, 8-16 = mild, ≥17= moderate to severe.

    Time frame: From date of enrollment until the date of end of study visit (EOS), assessed up to 8,5 months

  2. Remission rate

    Remission rate is defined as the number of patients with an HDRS-17 total score ≤ 7 divided by the total number of HDRS-17 evaluations from inclusion (V1) to End of study (EOS). The unit will be %.

    Time frame: From date of enrollment until the date of end of study visit (EOS), assessed up to 8,5 months

  3. Number of responders at Day 5

    The number of responders is defined as patients with ≥50% reduction in HDRS-17 total score at Day 5 (5 days after the end of the acute treatment) compared to the score at inclusion.

    Time frame: From enrollment date until the 5th day after the end of the acute treatment (Day 5), assessed up to 2 months and 3 weeks

  4. Number of responders at Month 1

    The number of responders is defined as patients with ≥50% reduction in HDRS-17 total score at Month 1 (M1), 1 month post end of acute treatment, compared to the score at inclusion.

    Time frame: From enrollment date until the Month 1 after the end of the acute treatment (M1), assessed up to 3,5 months

  5. Number of responders at Month 6 (End of Study)

    The number of responders is defined as patients with ≥50% reduction in HDRS-17 total score at Month 6 (M6), 6 months post end of acute treatment, compared to the score at inclusion. The M6 visit is the End of Study visit (EOS).

    Time frame: From date of enrollment until the date of end of study visit (EOS), assessed up to 8,5 months

  6. Number of partial responders throughout the study

    The number of partial responders is defined as patients with \>30% reduction in HDRS-17 total scores throughout the study, compared to the score at inclusion

    Time frame: From date of enrollment until the date of end of study visit (EOS), assessed up to 8,5 months

  7. Number of patients with a reduced score on the suicidal ideation item of the Columbia-Suicide Severity Rating Scale (C-SSRS) throughout the study compared to inclusion

    The number of patients with a reduced score on the suicidal ideation item of the C-SSRS throughout the study, compared to the score at inclusion

    Time frame: From date of enrollment until the date of end of study visit (EOS), assessed up to 8,5 months

  8. Clinical Global Impression-Severity (CGI-S) and CGI-improvement (CGI-I) scores

    CGI-S and CGI-I (Guy and Cleary, 1976, Berk et al., 2008, Nahas et al., 2013) scores at inclusion (V1), once a week during the randomized acute treatment period, at the end of the randomized acute treatment period (D5), and at M1 and M6. Improved versions of these scales will be used (Kadouri et al., 2007). The scores at each timepoint will be compared to the score at inclusion.

    Time frame: From date of enrollment until the date of end of study visit (EOS), assessed up to 8,5 months

  9. Columbia-Suicide Severity Rating Scale (C-SSRS) total scores

    C-SSRS (Greist et al., 2014) total scores at inclusion (V1), once a week during the acute treatment period, at M1 and End of study (EOS). The scores at each timepoint will be compared to the score at inclusion.

    Time frame: From date of enrollment until the date of end of study visit (EOS), assessed up to 8,5 months

  10. Quick Inventory of Depressive Symptomatology-Clinician rated (QIDS-C) total scores

    QIDS-C total score completed at inclusion (V1), once a week during the acute randomized treatment period (W1 to W6), at the end of the acute randomized treatment period (D5), at M1 and End of Study (EOS) visit. The score at each timepoint will be compared to the score at inclusion.

    Time frame: From date of enrollment until the date of end of study visit (EOS), assessed up to 8,5 months

  11. EQ-5D-5L total scores

    EQ-5D-5L total score completed at inclusion (V1), D5, M1 and End of Study (EOS) visit. The scores at each timepoint will be compared to the score at inclusion.

    Time frame: From date of enrollment until the date of end of study visit (EOS), assessed up to 8,5 months

  12. Mean time to Orientation Recovery (TOR)

    TOR is defined as the time required for a patient to remember 4 of the following 5 items: name, date of birth, age, place and day of the week. A stopwatch will be used to calculate the TOR. After the seizure, once participants open their eyes, each of the above guidance questions will be asked every 30 seconds until they are all answered correctly. The TOR will be assessed continuously for 90 min, and patients who fail to meet the TOR criteria will be given a score of 100 min. The TOR will be averaged for each patient and compared between the 3 study arms. The unit is : minutes.

    Time frame: From the end of the first session to the end of the last session (week 1 to week 6) of the acute treatment, assessed up to 6 weeks

  13. Number of adverse Events (AE) during the sessions of the acute treatment

    AE during the session of the acute treatment: heart rhythm disorder, prolonged seizure; after the session: confusion, memory impairment (retrograde amnesia, anterograde memory), headache, nausea, myalgia and agitation, alterations of executive and attentional functions

    Time frame: From week 1 until week 6 (acute treatment), assessed up to 6 weeks

  14. Patient VAS for memory disorders scores

    VAS for memory disorders (patient) scores at inclusion (V1), each day before the 1st session and at the end of the day, D5, M1 and End of Study (EOS). The minimum is 0 and the maximum is 100mm. Unit is millimeters.

    Time frame: From date of enrollment until the date of end of study visit (EOS), assessed up to 8,5 months

  15. Assessor VAS for memory disorders scores

    VAS for memory disorders (assessor) scores at inclusion (V1), each day before the 1st session and at the end of the day, D5, M1 and M6. The minimum is 0 and the maximum is 100mm. Unit is millimeters.

    Time frame: From date of enrollment until the date of end of study visit (EOS), assessed up to 8,5 months

  16. ElectroConvulsive therapy Cognitive Assessment (ECCA) total score

    ECCA (Hermida et al., 2020) total score completed at inclusion (V1), D5, M1 and Eond of Study (EOS). The scores at each timepoint will be compared to the score at inclusion.

    Time frame: From date of enrollment until the date of end of study visit (EOS), assessed up to 8,5 months

  17. Columbia Autobiographical Memory Interview-Short Form (AMI-SF) total scores

    AMI-SF (McElhiney et al., 1995, Semkovska et al., 2012) total score completed at inclusion (V1), D5, M1 and End of Study (EOS). The score at each timepoint will be compared to the score at inclusion.

    Time frame: From date of enrollment until the date of end of study visit (EOS), assessed up to 8,5 months

  18. Montreal Cognitive Assessment (MoCA) total scores

    MoCA (Nasreddine et al., 2005) total score completed at inclusion (V1), D5, M1 and End of Study (EOS). The score at each timepoint will be compared to the score at inclusion.

    Time frame: From date of enrollment until the date of end of study visit (EOS), assessed up to 8,5 months

  19. Verbal Fluency test total scores

    Verbal Fluency test from the French Standard Executive Neuropsychological Test Battery (Bayard, et al., 2025) total score completed at inclusion (V1), D5, M1 and End of Study (EOS). The score at each timepoint will be compared to the score at inclusion.

    Time frame: From date of enrollment until the date of end of study visit (EOS), assessed up to 8,5 months

  20. Rate of planned ECT/FEAST sessions realized (%)

    Number of ECT/FEAST sessions realized compared to the total number of planned ECT/FEAST sessions (%). Causes of sessions not realized will be described.

    Time frame: From Week 1 (start of acute treatment) until the date of End of study visit(EOS), assessed up to From date of enrollment until the date of end of study visit (EOS), assessed up to 7,5 months

  21. Mean EEG seizure duration

    Mean of EEG seizure duration per session (in seconds).

    Time frame: From the end of the first session until the end of the last session (week 1 to week 6) of the acute treatment, assessed up to 6 weeks

  22. Mean motor seizure duration

    Mean of motor seizure duration per session (in seconds).

    Time frame: From the end of the first session until the end of the last session (week 1 to week 6) of the acute treatment, assessed up to 6 weeks

  23. Number of Spontaneous Abnormal Brain Currents (SABc) per group

    SABc will be recorded as present or absent. The number of SABc present in each group will be analyzed

    Time frame: From the end of the first session (Week 1) until the date of the End of Study (EOS), assessed up to 7,5 months

  24. Rate of efficient electric or clinic crisis (%)

    Rate of efficient electric or clinic crisis according to Nobler criteria (Nobler et al., 1994) defined as the number of patients with efficient electric or clinic crisis divided by the total number of session delivered from start of acute treatment (W1) to End of study (EOS)

    Time frame: From the date of the first session (Week 1) until the date of the End of Study (EOS), assessed up to 7,5 months

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: No — GDPR in force in Europe and clinical trial :

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Jan 2030, 38 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2026
First posted
Oct 5, 2026
StartEst.
Nov 2, 2026
Primary completionEst.
Jan 2, 2030
CompletionEst.
Jul 2, 2030
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07857122
Collaborators
Neuromodulation Institute
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Nov 2, 2026 (estimated)
Primary completion
Jan 2, 2030 (estimated)
Completion
Jul 2, 2030 (estimated)
Last update
Oct 5, 2026

Study contacts

Philippe DOMENECH, MD, PhD
Contact
philippe.domenech@ghu-paris.fr
+33 1 45 65 89 76
Cécile MICHEL, MSc
Contact
cecile.bultez@ghu-paris.fr
Harold SACKHEIM, MD, PhD
study chair · Department of Psychiatry and Behavioral Sciences College of Medicine Medical University of South Carolina (MUSC) Charleston, South Carolina, USA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion